Genscript Biotech Corporation (GNNSF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Nanjing, China. Der aktuelle CEO ist Weihui Shao.
GNNSF hat IPO-Datum 2017-09-28, 5,568 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $3.1B.
Genscript Biotech Corporation is a global life science company founded in 2002 and headquartered in Nanjing, China, serving customers across North America, Europe, Asia Pacific, and internationally. The company operates through four primary segments: Life Science Services and Products, which provides gene synthesis, protein engineering, antibody development, and molecular diagnostics tools for research and drug discovery; Biologics Development Services, offering antibody drug development, gene therapy, and cell therapy development for pharmaceutical and biotech clients; Industrial Synthetic Biology Products, which manufactures microbial strains and industrial enzymes for food, pharmaceutical, and chemical industries; and Cell Therapy, focusing on chimeric antigen receptor T-cell therapies for cancer treatment. Through these integrated business segments, Genscript delivers comprehensive research products and development services that support basic biology studies, pharmaceutical discovery, disease diagnostics, and therapeutic development.
